{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:47:58Z","timestamp":1782730078058,"version":"3.54.5"},"reference-count":0,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologica"],"published-print":{"date-parts":[[2016]]},"abstract":"<b><i>Introduction:<\/i><\/b> Macular edema after cataract surgery (Irvine-Gass syndrome) or pars plana vitrectomy is a postoperative complication which can lead to permanent visual loss. Increased inflammatory substances, such as prostaglandins and cytokines, are discussed to be causative. Currently, there are no evidence-based guidelines for the treatment of postoperative macular edema. Intravitreal dexamethasone (DEX) could be effective by its anti-inflammatory effect. We examined the functional and morphological results of treatment with 0.7 mg intravitreal DEX implant (Ozurdex\u00ae). <b><i>Methods:<\/i><\/b> In an observational study, we analyzed visual acuity (logMAR), intraocular pressure (IOP), clinical findings, and the central macular thickness (CMT, optical coherence tomography [OCT] Spectralis\u00ae, Heidelberg Engineering, 30\u00b0 macular scan, 19 scans) of 12 eyes before and 1 month after the last DEX implantation (off-label use, Ozurdex\u00ae, Allergan, Inc., Irvine, CA, USA) for macular edema after cataract surgery or vitrectomy. Re-implantation was performed when OCT showed new intraretinal fluid along with a decrease in the patient's visual acuity. The mean follow-up was 14.4 \u00b1 10.6 months. <b><i>Results:<\/i><\/b> Twelve eyes of 12 patients (4 female, 8 male) with a mean age of 62.6 \u00b1 11.9 years were treated with a mean of 2.5 \u00b1 1.6 intravitreal DEX implant injections. Prior to injection, the visual acuity was 0.74 \u00b1 0.34 logMAR and the CMT was 608 \u00b1 129 \u00b5m. One month after the last injection (after a mean of 437 \u00b1 322 days), the CMT normalized (300 \u00b1 90 \u00b5m, <i>p<\/i> < 0.01) in all cases with a visual acuity of 0.49 \u00b1 0.43 logMAR (<i>p<\/i> < 0.01). After 8.1 \u00b1 5.3 months, recurring macular edema could be completely reduced by re-injection in 66% (8 patients). Four patients had no recurrence. Postinjection, the mean IOP was 17.4 \u00b1 6.8 mm Hg. Postinjection, 7 patients required topical antiglaucomatous therapy. <b><i>Conclusions:<\/i><\/b> Treatment with an intravitreal DEX implant is an effective therapy for postoperative macular edema. Each injection leads to a complete resorption of the edema with a significant increase in visual acuity.<\/jats:p>","DOI":"10.1159\/000448057","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T22:01:28Z","timestamp":1480716088000},"page":"181-185","source":"Crossref","is-referenced-by-count":25,"title":["Intravitreal Dexamethasone Implant for the Treatment of Postoperative Macular Edema"],"prefix":"10.1159","volume":"236","author":[{"given":"Andr\u00e9","family":"Klamann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Geerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schargus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Guthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2016,12,3]]},"container-title":["Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/448057","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/448057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/448057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:58:59Z","timestamp":1745427539000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000448057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,1,12]]}},"URL":"https:\/\/doi.org\/10.1159\/000448057","archive":["Portico"],"relation":{},"ISSN":["0030-3755","1423-0267"],"issn-type":[{"value":"0030-3755","type":"print"},{"value":"1423-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}